Phase 1/1b Pharmacokinetics Study of Oral MLN9708 in Patients With Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors With Normal Renal Function or Severe Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2019
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 14 Apr 2016 Planned End Date changed from 1 Nov 2015 to 1 Jun 2016.
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology